Announcement • 5h
Sectra AB (Publ) Proposes an Ordinary Dividend Sectra AB (publ) proposed that the 2026 AGM resolve on an ordinary dividend of SEK 1.30 (1.10) per share, considering the year's cash flow and Sectra's financial position. In addition, it is proposed that the Board be authorized to decide on the acquisition of own shares (see the year-end report) in order to enable the repurchase of Class B shares to secure the company's commitments under a new share-based incentive program that the Board intends to propose to the AGM. Reported Earnings • 12h
Full year 2026 earnings: EPS in line with analyst expectations despite revenue beat Full year 2026 results: EPS: kr2.93 (up from kr2.92 in FY 2025). Revenue: kr3.64b (up 9.9% from FY 2025). Net income: kr563.8m (flat on FY 2025). Profit margin: 16% (down from 17% in FY 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year. Live News • 22h
Sectra Delivers Record Year With Increased Dividends and Share Buyback Plans Sectra reported historically high sales and net profit for the 2025/2026 financial year, supported by its focus on medical imaging IT and secure communications.
Long-term investments in healthcare diagnostics and cyber defense were key contributors to the company’s full-year performance.
The Board proposed a higher ordinary dividend, an extra dividend, and authorization for share repurchases tied to a new long-term incentive program.
The combination of record financial results and proposed capital returns indicates that Sectra is using both dividends and buyback authorization to return cash to shareholders while continuing to allocate resources to longer-term strategic areas.
Investors may want to pay close attention to how the long-term incentive program and share repurchases influence ownership dilution and capital allocation over time. Announcement • May 23
Sectra AB (publ), Annual General Meeting, Sep 08, 2026 Sectra AB (publ), Annual General Meeting, Sep 08, 2026. Price Target Changed • May 18
Price target increased by 37% to kr302 Up from kr220, the current price target is an average from 3 analysts. New target price is 18% above last closing price of kr256. Stock is down 20% over the past year. The company is forecast to post earnings per share of kr2.94 for next year compared to kr2.92 last year. Announcement • Apr 17
Sectra AB (publ) (OM:SECT B) completed the acquisition of Oxipit, UAB. Sectra AB (publ) (OM:SECT B) entered into an agreement to acquire Oxipit, UAB on March 5, 2026. The acquisition will be funded from Sectra own funds and comprises an upfront cash consideration and an additional contingent consideration linked to commercial and regulatory milestones. The transaction is subject to customary closing conditions.
The transaction is expected to complete in March 2026.
Sectra AB (publ) (OM:SECT B) completed the acquisition of Oxipit, UAB on April 15, 2026. With the acquisition complete, Sectra now owns and will further develop ChestLink, Oxipit's flagship product and one of the most clinically validated examples of autonomous AI in radiology. This milestone strengthens Sectra's position as a provider of advanced, regulatory-approved AI solutions for diagnostic imaging. Announcement • Mar 10
Sectra Showcases MCP-Powered AI Innovations To Accelerate Enterprise Imaging At HIMSS Sectra showcased AI-driven solutions and Model Context Protocol (MCP)-powered prototypes at HIMSS 2026 designed to automate workflows and reduce operational complexity. By focusing on system consolidation, interoperability, seamless AI integration, and built-in multi-specialty reporting capabilities, Sectra's solutions accelerate diagnostics, reduce costs, and ease physician workload - enabling faster and better diagnoses. Sectra will demonstrate MCP, an emerging open standard gaining traction across industries, designed to simplify how AI integrates across enterprise imaging and integrated diagnostics, including genomics. The solution opens the door to a new paradigm for interfacing in medical IT. By leveraging MCP to power AI-driven interactions and interfaces, Sectra can automate workflows such as modality configuration, user role management, data analysis, and integration setup. This streamlines IT operations, reduces risk, and frees up resources to focus on patient-centered care. Examples of current and upcoming AI-driven capabilities include: AI for operations: Automates complex IT tasks using Operations AI powered by MCP, reducing manual effort and improving system efficiency. AI for workflows: Sectra's Amplifier Services marketplace features +100 validated AI applications for triaging, prioritization, and more, integrated seamlessly into workflows. AI for diagnostics: Empowers clinicians with tools like lesion segmentation, pathology cell counting, and automated chest X-ray analysis to enhance speed and accuracy. Autonomous AI in radiology: With the previously announced acquisition of Oxipit (closing expected March 2026), Sectra advances its autonomous AI capabilities in diagnostic imaging. Oxipit holds the first CE Class IIb certification for autonomous AI in chest X-ray analysis. This capability allows high-confidence normal cases to be cleared without radiologist review, initially in Europe, unlocking meaningful efficiency gains and cost reductions in healthcare. Sectra's enterprise imaging solution provides a unified platform for diagnostics needs based on large and unstructured data sets, such as imaging and genomics, enabling seamless collaboration across specialties such as radiology, pathology, genomics, and cardiology. After structuring the data, it is automatically forwarded into the EMR. Its scalable and modular design allows healthcare providers to expand from ology to ology and enterprise to enterprise while lowering operational costs and simplifying the adoption of AI. Reported Earnings • Mar 08
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: kr0.81 (down from kr1.37 in 3Q 2025). Revenue: kr919.8m (up 5.6% from 3Q 2025). Net income: kr155.1m (down 41% from 3Q 2025). Profit margin: 17% (down from 30% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Announcement • Mar 06
Sectra AB (publ) (OM:SECT B) entered into an agreement to acquire Oxipit, UAB. Sectra AB (publ) (OM:SECT B) entered into an agreement to acquire Oxipit, UAB on March 5, 2026. The acquisition will be funded from Sectra own funds and comprises an upfront cash consideration and an additional contingent consideration linked to commercial and regulatory milestones. The transaction is subject to customary closing conditions.
The transaction is expected to complete in March 2026. Price Target Changed • Mar 04
Price target decreased by 10% to kr220 Down from kr245, the current price target is an average from 2 analysts. New target price is 16% above last closing price of kr190. Stock is down 18% over the past year. The company is forecast to post earnings per share of kr2.81 for next year compared to kr2.92 last year. Buy Or Sell Opportunity • Feb 19
Now 22% overvalued Over the last 90 days, the stock has fallen 33% to kr189. The fair value is estimated to be kr155, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 29% in 2 years. Earnings are forecast to grow by 17% in the next 2 years. Price Target Changed • Dec 16
Price target increased by 18% to kr245 Up from kr208, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of kr254. Stock is down 6.5% over the past year. The company is forecast to post earnings per share of kr2.83 for next year compared to kr2.92 last year. Reported Earnings • Dec 14
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: kr0.77 (up from kr0.46 in 2Q 2025). Revenue: kr878.2m (up 14% from 2Q 2025). Net income: kr148.4m (up 69% from 2Q 2025). Profit margin: 17% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 45%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 23% per year. Announcement • Nov 26
Sectra Launches Its Built-In Reporting Solution in the Us-Accelerates Diagnostics for Improved Patient Care Sectra is introducing its built-in reporting solution for medical imaging, Sectra Reporting, to the US market. By unifying image review and reporting together in the diagnostic workflow, radiologists can work in a single application and avoid switching between systems. This shortens turnaround times, reduces workload, and supports faster care delivery. Sectra Reporting is a native, built-in solution that streamlines diagnostic workflows by integrating directly with imaging data and measurements. To free up time for the radiologist to focus on diagnostics rather than on documentation, the solution has AI capabilities such as automated impression generation and external AI results seamlessly integrated. At the same time, deep links to measurements, annotations, and lesion-tracking data allow radiologists to embed precise, actionable references in the report. Another vital part within reporting is to provide the radiologist with instant access to relevant image content. This reduces manual steps, minimizes dictation errors, and clarifies clinical results. Sectra's reporting solution also lowers cognitive load through automatic linking of prior exams and improves safety by preventing incorrect references. While maintaining support for third-party reporting solutions, Sectra offers customers the choice of a streamlined experience designed to accelerate reporting and enhance clinical collaboration. Announcement • Nov 24
Sectra to Present New Developments Designed to Make Radiology Workflows Even More Efficient by Deep Integration with AI Sectra will present new developments designed to make radiology workflows even more efficient, not least by deep integration with AI. Sectra will showcase its entire enterprise imaging solution that provides a unified platform for all imaging needs-while offering unique CT features, subspecialty-specific workflows, and seamless AI adoption that help radiologists work efficiently and maintain diagnostic precision. In booth #8113, Sectra will showcase its complete enterprise imaging portfolio comprised of diagnostic modules (radiology, cardiology, pathology, orthopaedics, ophthalmology, and genomics), with its VNA and PACS at its core. In the latest KLAS report for customer satisfaction, Sectra's PACS was placed first for the 12th consecutive year and the KLAS Research surveys indicate that Sectra is the preferred choice among large US customers, with almost twice the rate of the second-ranked vendor. The enterprise imaging solution is delivered as a Software as a Service, independently audited and certified for cloud security by the Cloud Security Alliance (CSA). Selected highlights featured at Sectra's booth #8113 at RSNA include: Sectra's integrated reporting: New AI features in reporting to remove manual steps. Radiologists can dictate freely and automatically generate formatted impressions directly in the report, allowing for focus on diagnostics rather than documentation. Sectra's AI solutions: AI as a Service to accelerate adoption of AI in efficient clinical workflows. Healthcare providers can buy, activate and use validated algorithms quickly, allowing them to realize value from AI sooner. Sectra's PACS integrated photon-counting CT support: Integrated PCCT post-processing in the diagnostic application to deliver superior image clarity, lower patient radiation dose, and accelerate acquisition, allowing radiologists to diagnose confidently while streamlining workflow. Sectra's integrated clinical education portal: Sectra Education Portal to enhance learning for radiologists and radiographers. It provides a realistic imaging training environment with a diagnostic toolbox and access to personal or shared case libraries, supporting continuous skill development. Sectra Enterprise Research: A multi-modality solution that streamlines clinical research with cohort management, batch anonymization, and full clinical functionality-delivered as a cost-efficient and secure Software as a Service. Announcement • Nov 10
Sectra Launches Secure European Mobile Communication Platform for Sensitive But Formally Unclassified Information Sectra announced the launch of Sectra Tiger/E Managed Service-a sovereign, fully managed collaboration platform designed to meet the evolving needs of authorities, municipalities, essential entities, and corporations. The new solution enables secure, scalable, and easy-to-use mobile communication for sensitive but unclassified information. It supports calls, video, and chat with strong encryption, provides endpoint security, and is designed for high availability and broad usability. Sectra Tiger/E Managing Service combines hardened Samsung Knox devices, a dual-environment architecture, and a quantity-resilient VPN in a service model that strengthens national resilience. By separating two secure zones-one for sensitive collaboration and one for everyday tasks-the platform lets users work securely withoutosing usability or mobility. Altogether, the service ensures high availability, end-to-end encrypted communication, strong endpoint security and an infrastructure designed for national resilience and regulatory compliance. As it is a fully managed service by Sectra, it reduces the burden on internal IT teams and ensures the reliability essential for organizations that can't afford downtime. Designed to support both everyday sensitive communication and time-critical collaboration, Sectra Tiger/E Manage Service gives users the flexibility and mobility to work securely-whether handling business secrets, coordinating daily operations, or responding in a crisis. The solution is built on Sectra's long-standing experience in developing RESTRICTED, SECRET, and TOP SECRET solutions. While not intended for classified communication, it brings proven security practices and threat analysis methodology into a robust platform designed for sensitive collaboration. The Sectra Tiger/E (where "E" stands for "essentials") complements the suite of established solutions, such as Sectra Tiger/S (SECRET). In this context, "essentials" refers to information that requires enhanced security for sensitive communication and collaboration. Sectra Tiger/EManaged Service is available now to support organizations seeking to enhance security, ensure jurisdiction control, and enable encrypted collaboration in a rapidly changing threat landscape. Board Change • Oct 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Employee Representative Deputy Director Pontus Svard was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 10
Sectra AB (Publ) Approves Ordinary Dividend, Payable on September 16, 2025 Sectra AB (publ) at its AGM held on September 9, 2025, approved ordinary dividend amounts to SEK 1.10 per share and the extra dividend to SEK 1.00 per share, representing a total of SEK 2.10 per share. The remaining earnings will be carried forward. The record date for entitlement to the dividend is September 11, 2025. The dividend is expected to be paid on September 16, 2025, through Euroclear Sweden AB. Reported Earnings • Sep 05
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: kr0.53 (up from kr0.42 in 1Q 2025). Revenue: kr788.9m (up 7.1% from 1Q 2025). Net income: kr102.8m (up 28% from 1Q 2025). Profit margin: 13% (up from 11% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 8.0%. Earnings per share (EPS) exceeded analyst estimates by 15%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Sep 03
Upcoming dividend of kr2.10 per share Eligible shareholders must have bought the stock before 10 September 2025. Payment date: 16 September 2025. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Swedish dividend payers (3.9%). Lower than average of industry peers (1.2%). Announcement • Aug 13
Sectra Receives the Security Attestation Cloud Computing Compliance Criteria Catalogue (C5) for Its Software-As-A-Service Sectra has received the security attestation Cloud Computing Compliance Criteria Catalogue (C5) for its Software-as-a-Service (SaaS) for enterprise imaging, Sectra One Cloud. With Sectra being one of the first in the field in Germany to receive this attestation, healthcare providers are now able to adopt the cloud service and as such strengthen security and reduce IT burden. The C5 framework is created by Germany's national cybersecurity authority Bundesamt fur Sicherheit in der Informationstechnik (BSI), an authority that defines IT-Security requirements for all governmental systems in Germany. The attestation aims to strengthen the transparency and security of cloud-based solutions and contains a collection of requirements that defines what security measures a cloud service provider should have implemented to sell services handling patient data. Sectra One Cloud, which operates within the Microsoft Azure public cloud environment, now has both C5 and CSA STAR Level 2. While the CSA STAR Level 2 certificate, received in 2024, applies to global standards, the C5 attestation addresses requirements specific to the German market. Together, these certificates reflect Sectra's proactive leadership in advancing cloud security and transparency for the global healthcare market. Reported Earnings • Jun 07
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: kr2.92 (up from kr2.22 in FY 2024). Revenue: kr3.31b (up 9.2% from FY 2024). Net income: kr563.4m (up 32% from FY 2024). Profit margin: 17% (up from 14% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 06
Sectra AB (publ), Annual General Meeting, Sep 09, 2025 Sectra AB (publ), Annual General Meeting, Sep 09, 2025. Price Target Changed • Jun 03
Price target increased by 11% to kr268 Up from kr240, the current price target is an average from 2 analysts. New target price is 17% below last closing price of kr324. Stock is up 40% over the past year. The company is forecast to post earnings per share of kr3.18 for next year compared to kr2.22 last year. Reported Earnings • Mar 14
Third quarter 2025 earnings released: EPS: kr1.37 (vs kr0.30 in 3Q 2024) Third quarter 2025 results: EPS: kr1.37 (up from kr0.30 in 3Q 2024). Revenue: kr871.3m (up 22% from 3Q 2024). Net income: kr264.0m (up 357% from 3Q 2024). Profit margin: 30% (up from 8.1% in 3Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 19% per year. New Risk • Dec 16
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: kr3.4m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company. Reported Earnings • Dec 13
Second quarter 2025 earnings released: EPS: kr0.46 (vs kr0.78 in 2Q 2024) Second quarter 2025 results: EPS: kr0.46 (down from kr0.78 in 2Q 2024). Revenue: kr772.9m (down 4.1% from 2Q 2024). Net income: kr87.8m (down 42% from 2Q 2024). Profit margin: 11% (down from 19% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 15% per year. Board Change • Dec 06
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Employee Representative Deputy Director Alva Mardsjo was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Employee Representative Deputy Director Alva Mardsjo was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Oct 09
Price target increased by 43% to kr240 Up from kr168, the current price target is provided by 1 analyst. New target price is 15% below last closing price of kr282. Stock is up 120% over the past year. The company is forecast to post earnings per share of kr2.74 for next year compared to kr2.22 last year. Recent Insider Transactions • Oct 07
Insider recently sold kr3.4m worth of stock On the 1st of October, Marie Tragardh sold around 12k shares on-market at roughly kr283 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr5.6m more than they bought in the last 12 months. Reported Earnings • Sep 06
First quarter 2025 earnings released: EPS: kr0.42 (vs kr0.32 in 1Q 2024) First quarter 2025 results: EPS: kr0.42 (up from kr0.32 in 1Q 2024). Revenue: kr739.5m (up 23% from 1Q 2024). Net income: kr80.4m (up 31% from 1Q 2024). Profit margin: 11% (in line with 1Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • Jul 05
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: kr2.22 (up from kr1.95 in FY 2023). Revenue: kr3.04b (up 26% from FY 2023). Net income: kr428.4m (up 14% from FY 2023). Profit margin: 14% (down from 16% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jun 13
Price target increased by 12% to kr168 Up from kr150, the current price target is an average from 2 analysts. New target price is 35% below last closing price of kr257. Stock is up 34% over the past year. The company is forecast to post earnings per share of kr2.73 for next year compared to kr2.22 last year. Reported Earnings • Jun 06
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: kr2.22 (up from kr1.95 in FY 2023). Revenue: kr3.04b (up 26% from FY 2023). Net income: kr428.4m (up 14% from FY 2023). Profit margin: 14% (down from 16% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 06
Sectra AB (publ) to Report Fiscal Year 2025 Results on Jun 05, 2025 Sectra AB (publ) announced that they will report fiscal year 2025 results at 8:15 AM, Central European Standard Time on Jun 05, 2025 Announcement • Jun 05
Sectra Adds It Solution for Genomics in Cancer Diagnostics-First Deployment At A Us Health System Sectra launched a new diagnostic IT module for genomics within molecular pathology, developed in collaboration with the University of Pennsylvania Health System in the US. The new solution, now clinically live, enables hospitals to predict how an individual cancer patient may respond to different treatments based on genomic information. This will in turn have the potential to significantly impact patient care. The solution will be integrated with Sectra's other solutions for radiology and pathology. Analysis of genetic information, genomics, is increasingly used in healthcare to better diagnose and treat patients. Individualized care based on, among other data, genetic information is often referred to as precision medicine and is a rapidly growing field. The new solution from Sectra helps healthcare professionals analyze genetic information to enhance and speed up cancer diagnostics. The solution at Pennsylvania Health System is provided as a service, fully integrated with the medical record system, and Sectra takes full responsibility for the maintenance of the solution. This believes IT burdens at the health system and allows them to fully harness the potential and value of genomic data. It is now commercially available in the US, with the University of Pennsylvania Health system being the first to implement it. The IT solution for genomic information is, despite not being based on images, a part of Sectra's enterprise imaging solution. The enterprise imaging solution provides a unified strategy for all imaging and associated needs while lowering operational costs. The scalable and modular solution allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Announcement • Apr 30
Sectra and Leica Biosystems Gains FDA Clearance to Utilize DICOM Images for Pathology Diagnostics Sectra together with Leica Biosystems, Imaging Inc.'s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA). This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, which marks a significant step towards standardization in this field. Sectra received its first FDA clearance during the pandemic, in 2020. The pandemic made the need and value of remote work even in the field of pathology obvious and has helped boost the adoption of digital pathology in the US. Today, the value of accessing, sharing and reviewing digital images is clear and the market for digital pathology in the US, as well as other countries, is growing rapidly. The FDA clearance includes: Sectra's digital pathology solution when used with Leica Biosystems Aperio GT 450 DX. SVS and DICOM file formats. Sectra UniView and IDS7 cloud-based and on-premises installation. A digital pathology solution provides instant and, if necessary, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes. This optimizes the workflows for pathologists, leading to enhanced efficiency in cancer diagnostics. The pathology solution is part of Sectra's enterprise imaging solution, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Reported Earnings • Mar 10
Third quarter 2024 earnings released: EPS: kr0.30 (vs kr0.38 in 3Q 2023) Third quarter 2024 results: EPS: kr0.30 (down from kr0.38 in 3Q 2023). Revenue: kr714.0m (up 20% from 3Q 2023). Net income: kr57.8m (down 20% from 3Q 2023). Profit margin: 8.1% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 20% per year. Announcement • Mar 08
Sectra AB (publ) to Report Q1, 2025 Results on Sep 06, 2024 Sectra AB (publ) announced that they will report Q1, 2025 results at 8:15 AM, Central European Standard Time on Sep 06, 2024 Recent Insider Transactions • Feb 04
Chief People & Brand Officer recently sold kr390k worth of stock On the 30th of January, Lisa Everhill sold around 2k shares on-market at roughly kr195 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth kr1.8m. Insiders have been net sellers, collectively disposing of kr2.2m more than they bought in the last 12 months. Recent Insider Transactions • Jan 25
Insider recently sold kr1.8m worth of stock On the 19th of January, Marie Tragardh sold around 10k shares on-market at roughly kr185 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Price Target Changed • Jan 11
Price target increased by 7.5% to kr143 Up from kr133, the current price target is an average from 2 analysts. New target price is 19% below last closing price of kr176. Stock is up 21% over the past year. The company is forecast to post earnings per share of kr2.14 for next year compared to kr1.95 last year. Announcement • Dec 21
Sectra AB (publ), Annual General Meeting, Sep 10, 2024 Sectra AB (publ), Annual General Meeting, Sep 10, 2024. Reported Earnings • Dec 16
Second quarter 2024 earnings released: EPS: kr0.78 (vs kr0.49 in 2Q 2023) Second quarter 2024 results: EPS: kr0.78 (up from kr0.49 in 2Q 2023). Revenue: kr807.9m (up 41% from 2Q 2023). Net income: kr150.6m (up 60% from 2Q 2023). Profit margin: 19% (up from 16% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 06
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr603.0m (up 22% from 1Q 2023). Net income: kr61.6m (up 14% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Reported Earnings • Jul 07
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: kr1.95 (up from kr1.63 in FY 2022). Revenue: kr2.41b (up 21% from FY 2022). Net income: kr375.0m (up 19% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.3%. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year. Announcement • Jun 03
Sectra AB (Publ) Proposes Dividend The Board of Directors and President of Sectra AB (publ) have proposed that the Annual General Meeting (AGM) resolve that SEK 1.10 SEK per share be distributed to the shareholders through a share redemption program. Reported Earnings • Jun 02
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: kr1.95 (up from kr1.63 in FY 2022). Revenue: kr2.41b (up 21% from FY 2022). Net income: kr375.0m (up 19% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.3%. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. 
